ATAI:NSD-ATAI Life Sciences N.V. Common Shares (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.32

Change

+0.58 (+4.22)%

Market Cap

USD 2.11B

Volume

0.29M

Avg Analyst Target

USD 27.30 (+90.64%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany. Address: Krausenstrasse 9-10, Berlin, Germany, 10117

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.86 (-1.41%)

USD139.56B 40.85 31.63
BNTX BioNTech SE

-13.62 (-4.66%)

USD70.91B 16.26 11.68
REGN Regeneron Pharmaceuticals Inc

-2.55 (-0.43%)

USD62.24B 10.69 7.94
VRTX Vertex Pharmaceuticals Incorpo..

-3.13 (-1.70%)

USD47.75B 24.27 16.15
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-16.37 (-4.27%)

USD35.80B N/A N/A
SGEN Seagen Inc

-3.09 (-1.74%)

USD32.33B 55.44 43.27
GMAB Genmab A/S

-0.46 (-1.01%)

USD30.35B 77.92 9.04
ALNY Alnylam Pharmaceuticals Inc

-6.55 (-3.31%)

USD23.50B N/A N/A
RPRX Royalty Pharma plc

-0.93 (-2.46%)

USD22.91B 30.56 12.22

ETFs Containing ATAI

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 789.44% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 789.44% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 789.44% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 789.44% 98% A+ 99% A+
Trailing 5 Years  
Capital Gain 303.38% 83% B 87% B+
Dividend Return 179.44% 100% A+ 100% A+
Total Return 482.82% 89% B+ 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 80.38% 85% B 91% A-
Dividend Return 31.47% 75% C 100% A+
Total Return 111.85% 89% B+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 285.84% 8% F 5% F
Risk Adjusted Return 39.13% 66% D 55% F
Market Capitalization 2.11B 85% B 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.30 77% C+ 93% A
Price/Book Ratio 4.97 36% F 29% F
Price / Cash Flow Ratio -101.77 95% A 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -9,999,999.00% 0% N/A 3% F
Return on Invested Capital -132.79% 11% F 5% F
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 2.28% 71% C- 84% B
Technical Ratios  
Short Ratio 7.61 29% F 16% F
Short Percent 1.75% 81% B- 64% D
Beta 2.82 4% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector